{"created":"2020-08-30T20:00:28.159837+00:00","id":3126,"links":{},"metadata":{"_buckets":{"deposit":"966f31a3-27d8-45a8-a23d-d66ee485e9cf"},"_deposit":{"id":"3126","owners":[],"pid":{"revision_id":0,"type":"recid","value":"3126"},"status":"published"},"_oai":{"id":"oai:meral.edu.mm:recid/3126","sets":["1582963366982:1597649530495"]},"communities":["um1"],"item_1583103067471":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Comparison of Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung and Normal Subjects","subitem_1551255648112":""}]},"item_1583103085720":{"attribute_name":"Description","attribute_value_mlt":[{"interim":"
Relation of inflammation and cancer can be proven in most of the studies. Epidermal growth factor receptor (EGFR) overexpression is one of the commonest causes of non-small cell carcinoma of lung cancer (NSCLC). Cyclooxygenase-2 (COX-2) enzyme and its products; prostaglandin, prostacyclin, thromboxane are involved in inflammation. The aim of the study was to compare the serum epidermal growth factor receptor and cyclooxygenase-2 levels between patients with non-small cell carcinoma of lung and healthy controls. This study included 53 patients diagnosed as NSCLC and 16 apparently healthy controls. In 53 patients, 3 patients were
\ndiagnosed as adenocarcinoma and 50 patients were diagnosed as squamous cell carcinoma (SCC) of lung. In both subjects, serum EGFR and COX-2 levels were determined by ELISA. The mean serum EGFR and COX-2 levels of NSCLC patients were significantly higher than those of healthy controls (170.10±13.80 vs. 3.56±0.48 ng/ml) and (13.21±3.17 vs. 0.62± 0.15 ng/ml), respectively (p<0.001 in both). Both the mean serum EGFR and COX-2 levels of SCC patients (172.10±14.30 ng/ml and 13.60±3.34
\nng/ml) were significantly higher than those of healthy controls (p<0.001 in both).